Effects of candesartan for middle-aged and elderly women with hypertension and menopausal-like symptoms

Hypertension Research

Volumn 29, Issue 12, 2006, Pages 1007-1012

  Ikeda, Hideo ^a   Inoue, Teruo ^b   Uemura, Shumpo ^a   Kaibara, Ryota ^a   Tanaka, Hiroyuki ^a   Node, Koichi ^b  

^a Saga Medical Association   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

Candesartan; Hypertension; Menopausal like symptom; Middle aged or elderly women; Simplified menopausal index

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CANDESARTAN HEXETIL; RENIN;

ADULT; ARTHRALGIA; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FROZEN SHOULDER; HEADACHE; HEART PALPITATION; HEART RATE; HOT FLUSH; HUMAN; HYPERTENSION; INHIBITION KINETICS; INSOMNIA; INTERVIEW; IRRITABILITY; LOW BACK PAIN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTICENTER STUDY; NAUSEA; NIGHT SWEAT; PRESCRIPTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCORING SYSTEM; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; VERTIGO;

AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; FEMALE; HUMANS; HYPERTENSION; MENOPAUSE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES;

EID: 33846786783     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.1007     Document Type: Article

References (24)

1. Takamatsu K, Ohta H, Makita K, et al: Effects of counseling on climacteric symptoms in Japanese postmenopausal women. J Obstet Gynecolol 2001; 27: 133-140.
2. Saavedra JM, Ando H, Armando I, et al: Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists. Regul Pept 2005; 128: 227-238.
3. Koyama T: Climacteric disorders. Obstet Gynecol Ther 1994; 69: 506-509 (in Japanese).
4. Bradshaw K: Hormone replacement therapy in hypertensive postmenopausal women. Role of the gynecologist. in Safer M, Stimpel M, Zanchetti A (eds): Hypertension in Post-menopausal Women. Berlin and Heidelberg, Springer-Verlag, 1994, pp 45-51.
5. Stacssen J, Bulpitt CJ, Fagard R, et al: The influence of menopause on blood pressure. J Hum Hypertens 1989; 3: 427-433.
6. Anastos R, Charney P, Charon RA, et al, The Women's Caucus, Working Group on Women's Health of the Society of Geneal Internal Medicine: Hypetension in women: what is really known? Ann Intern Med 1991; 115: 287-293.
7. Hjemdahl P, Wiklund I: Quality of life on antihypertensive drug therapy: end point or marketing exercise? Hypertension 1992; 10: 1437-1446.
8. Barnet DB: Assessment of quality of life: a medical imperative. Am J Cardiol 1991; 67: 41C-44C.
9. Wenger NK: Assessment of quality of life: a medical imperative. Cardiovasc Drug Ther 1988; 1: 553-558.
10. Dahlöf B, Innocenti AD, Elmfeldt D, et al: Felodipine-metoprolol combination tablet: maintained health-related quality of life in the presence of substantial blood pressure reduction. Am J Hypertens 2005; 18: 1313-1319.
11. Schulte KL, Fischer M, Lenz T, et al: Efficacy and tolerability of candesartan cilexetil monotherapy or in combination with other antihypertensive drugs: results of the AURA study. Clin Drug Invest 1999; 18: 453-460.
12. Malmqvist K, Kahan T, Dahl M: Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide. Am J Hypertens 2000; 13: 504-511.
13. Kloner RA, Weinberger M, Pool JL, et al: Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Am J Cardiol 2001; 87: 727-731.
14. Kirpizidis H, Stavrati A, Geleris P: Assessment of quality of life in a randomized clinical trial of candesartan only or in combination with DASH diet for hypertensive patients. J Cardiol 2005; 46: 177-182.
15. Mercuro G, Zonc S, Pilia I, et al: Effects of acute administration of transdermal estrogen on postmenpausal women with systemic hypertension. Am J Cardiol 1997; 80: 652-655.
16. Owada K: Efficacy of candesartan in the treatment of migraine in hypertensive patients. Hypertens Res 2004; 27: 441-446.
17. Nickenig G, Bäumer AT, Grohe C, et al: Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 1998; 97: 2197-2201.
18. Suzuki H, Kanno Y, for the Efficacy of Candesartan on Outcome in Saitama Trial (E-COST) Group: Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 2005; 28: 307-314.
19. Pfeffer MA, Swedberg K, Granger CB, et al: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-766.
20. McMurray JJ, Ostergren J, Swedberg K, et al: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771.
21. Yusuf S, Pfeffer MA, Swedberg K, et al: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003; 362: 777-781.
22. Lithell H, Hanson L, Skoog I, et al: The Study on Cognition and Prognosis in Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886.
23. Dohi Y, Ohashi M, Sugiyama M, et al: Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res 2003; 26: 691-697.
24. Kubota T, Sagara Y, Nakazawa N, et al: The influence of pregnancy and delivery on the climacteric symptom. Acta Obstet Gynaecol Jpn 1996; 48: 1-8 (in Japanese).